Streetbeat News

Partnerships

BIOC

PSTV

Biocept Inc (BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (PSTV). The agreement expands the laboratory services agreement between the two companies. Plus Therapeutics is using CNSide in a clinical trial to treat patients with carcinomas and/or melanomas. Plus will pay Biocept an upfront fee of $150,000 in stock, plus $6,000 per CSF tumor cell enumeration analysis performed in Biocept's laboratory before the completion of the technology transfer.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 1:18 pm

DATS

DatChat (NASDAQ:DATS), a blockchain, cybersecurity and social media company, has reported over 100,000 active users on its metaverse platform, Habytat. The platform offers users a private social networking experience and unique features such as NFT-deeded land and houses. The company has also signed a Memorandum of Understanding with Cloud Water Brands to promote its products within Habytat. DatChat has recently filed a patent for technology that enables secure access to group-based digital assets across its platforms.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 1:05 pm

GSAT

MARK

NBSE

Insiders at Remark Holdings, NeuBase Therapeutics, and Globalstar have recently made significant purchases of their companies' stocks. Remark Holdings posted a narrower Q2 loss, Symetryx Corporation acquired a 20% stake in NeuBase Therapeutics and urged a special $1 per share dividend, and Globalstar appointed a new CEO and announced a licensing agreement with XCOM Labs.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 1:03 pm

AIHS

Senmiao Technology has signed a strategic cooperation agreement with Zhongfu Wuyou Shenzhen Technology. The details of the agreement were not disclosed in the news.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 1:01 pm

AMZN

CMCSA

DIS

NFLX

PARA

SONY

WMD

Israel has partnered with Russia in a filmmaking pact, drawing backlash amid the ongoing conflict with Ukraine. Major U.S. film companies, including Netflix, Amazon, Warner Bros. Discovery, Disney, Sony, Paramount Global, and Comcast, have stopped releasing movies in Russia and some have left the country completely. The partnership between Israel and Russia could potentially impact movie and television companies partnered in Israel or on Israeli films, as they may face difficult decisions regarding films that could end up being screened in or financed by Russia.

Portfolio Pulse from Chris Katje

September 08, 2023 | 12:52 pm

BIOC

Biocept has entered into a non-exclusive licensing agreement for CNSide with Plus Therapeutics. This news has led to an increase in Biocept's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:36 pm

LEBGF

TOON

Legible Inc. has secured worldwide rights to publish and distribute Stan Lee's Workforce in a deal with Kartoon Studios. This expands Legible's existing partnership with Kartoon Studios and positions the company as an emerging global publisher. The deal also includes the development and distribution of approximately 12 original comic book series based on never-before-seen Stan Lee creations.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:35 pm

AIRI

Air Industries Group (NYSE:AIRI) has secured the welding equipment, related tooling and peripheral equipment used to weld the arresting gear that secures the E-2D aircraft's tail hook. This makes Air Industries the sole provider of this mission-critical welding process for the E-2D platform. The E-2D Advanced Hawkeye is a carrier-based, battle-management aircraft, and approximately 65 E-2Ds are active in the fleet, which is forecast to expand by more than 40% to 93 aircraft in 2027. Air Industries' E-2D product backlog is close to $20 million, or 29% of their total backlog.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:34 pm

BRTX

BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced the activation of Northwell Health in the company's Phase 2 clinical trial targeting chronic lumbar disc disease. This activation allows for patients in New York to participate in the BRTX-100 trial. The company's lead clinical candidate, BRTX-100, is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow and limited oxygen supply. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:33 pm

BLK

FXI

China's Securities Regulator has held discussions with both domestic and overseas investors, including Temasek, Bridgewater, and BlackRock. The details of the discussions were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:19 pm